STUDY DESIGN: Randomized double-blinded placebo-controlled trial~ELIGIBILITY~Inclusion criteria:~age 18 years and older~participants will need daily access to use of a smartphone for at least six weeks from time of enrollment~Positive COVID-19 test within 10 days of date of enrollment~not already hospitalized for treatment of COVID~Exclusion criteria:~pregnant~already hospitalized for treatment of COVID~PROTOCOL~50:50 randomization: half of participants will take NAC, half will take placebo~Participants will take NAC/placebo following this outpatient protocol:~2400 mg x 1 PO then~1200 mg PO BID x 14 days~Participants will complete an online symptom-tracker for six weeks (daily for three weeks, weekly for three weeks)
The objective of this study is to determine whether oral NAC is effective at attenuating COVID-19 disease symptom severity and duration of symptoms.